Last reviewed 2026-04-23 · How we verify

KP-100LI

Kringle Pharma, Inc. · Phase 3 active Small molecule

KP-100LI is a SGLT2 inhibitor Small molecule drug developed by Kringle Pharma, Inc.. It is currently in Phase 3 development for Type 2 diabetes. Also known as: Hepatocyte Growth Factor, HGF.

KP-100LI is a small molecule that targets the SGLT2 receptor.

KP-100LI is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	KP-100LI
Also known as	Hepatocyte Growth Factor, HGF
Sponsor	Kringle Pharma, Inc.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

By inhibiting SGLT2, KP-100LI reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Diarrhea
Vomiting

Key clinical trials

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KP-100LI CI brief — competitive landscape report
KP-100LI updates RSS · CI watch RSS
Kringle Pharma, Inc. portfolio CI

Frequently asked questions about KP-100LI

What is KP-100LI?

KP-100LI is a SGLT2 inhibitor drug developed by Kringle Pharma, Inc., indicated for Type 2 diabetes.

How does KP-100LI work?

KP-100LI is a small molecule that targets the SGLT2 receptor.

What is KP-100LI used for?

KP-100LI is indicated for Type 2 diabetes.

Who makes KP-100LI?

KP-100LI is developed by Kringle Pharma, Inc. (see full Kringle Pharma, Inc. pipeline at /company/kringle-pharma-inc).

Is KP-100LI also known as anything else?

KP-100LI is also known as Hepatocyte Growth Factor, HGF.

What drug class is KP-100LI in?

KP-100LI belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is KP-100LI in?

KP-100LI is in Phase 3.

What are the side effects of KP-100LI?

Common side effects of KP-100LI include Nausea, Diarrhea, Vomiting.

What does KP-100LI target?

KP-100LI targets SGLT2 and is a SGLT2 inhibitor.

Drug class: All SGLT2 inhibitor drugs
Target: All drugs targeting SGLT2
Manufacturer: Kringle Pharma, Inc. — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes
Also known as: Hepatocyte Growth Factor, HGF

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing